Medosome Biotec

Focus: Medosome Biotec is a public-stage biotechnology company headquartered in Alachua, FL, focused on small molecules and biologics development. The company operates with minimal disclosed employee count and financial data.

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Medosome Biotec

AI assessmentNot Hiring

No open roles listed right now. Follow Medosome Biotec to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Dichloroacetate

Healthy

PHASE_1

Clinical Trials (1)

NCT02690285A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers

Phase 1

Help build intelligence for Medosome Biotec

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with Phase 3 program in Pyruvate Dehydrogenase Complex Deficiency, a rare disease with limited treatment options
Public company status provides potential equity upside and greater operational transparency than private peers
Focused therapeutic strategy in small molecules and biologics reduces organizational complexity

Watch Out For

Zero active job openings and minimal disclosed headcount suggests early-stage operations or contraction phase
No published revenue, R&D spend, or cash position data raises questions about financial stability and runway
Single drug candidate (Dichloroacetate) across two indications concentrates pipeline risk heavily on one molecule

Generated by Claude from Medosome Biotec's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Dichloroacetate

Pyruvate Dehydrogenase Complex Deficiency

PHASE_3

Clinical Trials (1)

NCT02616484Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo